Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Xeroderma Pigmentosum, Complementation Group D
|
111 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.100 | 0.938 | 32 | 2001 | 2019 | |||||
Carcinoma of lung
|
1204 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.800 | 0.963 | 27 | 2003 | 2019 | |||||
Malignant neoplasm of lung
|
1142 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.100 | 0.962 | 26 | 2003 | 2019 | |||||
Primary malignant neoplasm of lung
|
981 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.100 | 0.962 | 26 | 2003 | 2019 | |||||
Breast Carcinoma
|
2793 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.100 | 0.842 | 19 | 2004 | 2019 | |||||
Malignant neoplasm of breast
|
3417 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.100 | 0.842 | 19 | 2004 | 2019 | |||||
Colorectal Carcinoma
|
1962 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.100 | 0.800 | 15 | 2005 | 2019 | |||||
Glioma
|
353 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.100 | 1.000 | 11 | 2005 | 2017 | |||||
Malignant Neoplasms
|
1641 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.100 | 0.909 | 11 | 2002 | 2015 | |||||
Non-Small Cell Lung Carcinoma
|
712 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.100 | 0.909 | 11 | 2011 | 2017 | |||||
Malignant neoplasm of stomach
|
615 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.090 | 0.778 | 9 | 2011 | 2018 | |||||
Primary malignant neoplasm
|
1374 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.090 | 0.889 | 9 | 2002 | 2015 | |||||
Stomach Carcinoma
|
652 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.090 | 0.778 | 9 | 2011 | 2018 | |||||
Bladder Neoplasm
|
281 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.080 | 1.000 | 8 | 2007 | 2014 | |||||
Carcinoma of bladder
|
309 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.080 | 1.000 | 8 | 2007 | 2014 | |||||
Childhood Osteosarcoma
|
151 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.080 | 0.625 | 8 | 2012 | 2018 | |||||
Malignant neoplasm of colon and/or rectum
|
502 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.080 | 0.750 | 8 | 2005 | 2016 | |||||
Malignant neoplasm of urinary bladder
|
316 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.080 | 1.000 | 8 | 2007 | 2014 | |||||
melanoma
|
515 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.080 | 0.875 | 8 | 2005 | 2018 | |||||
Neoplasms
|
1644 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.080 | 0.875 | 8 | 2005 | 2017 | |||||
Osteosarcoma
|
178 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.080 | 0.625 | 8 | 2012 | 2018 | |||||
Osteosarcoma of bone
|
151 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.080 | 0.625 | 8 | 2012 | 2018 | |||||
Malignant neoplasm of prostate
|
1082 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.070 | 0.857 | 7 | 2004 | 2017 | |||||
Prostate carcinoma
|
1168 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.070 | 0.857 | 7 | 2004 | 2017 | |||||
Leukemia, Myelocytic, Acute
|
6892 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.060 | 0.833 | 6 | 2006 | 2019 |